A detailed history of Fairfield Financial Advisors, LTD transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Fairfield Financial Advisors, LTD holds 20 shares of TSVT stock, worth $94. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20
Holding current value
$94
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$3.6 - $5.79 $72 - $115
20 New
20 $77,000

Others Institutions Holding TSVT

About 2seventy bio, Inc.


  • Ticker TSVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,873,600
  • Market Cap $179M
  • Description
  • 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...
More about TSVT
Track This Portfolio

Track Fairfield Financial Advisors, LTD Portfolio

Follow Fairfield Financial Advisors, LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fairfield Financial Advisors, LTD, based on Form 13F filings with the SEC.

News

Stay updated on Fairfield Financial Advisors, LTD with notifications on news.